NZ567458A - Method of indentifying transmembrane protein-interacting compounds - Google Patents

Method of indentifying transmembrane protein-interacting compounds

Info

Publication number
NZ567458A
NZ567458A NZ567458A NZ56745803A NZ567458A NZ 567458 A NZ567458 A NZ 567458A NZ 567458 A NZ567458 A NZ 567458A NZ 56745803 A NZ56745803 A NZ 56745803A NZ 567458 A NZ567458 A NZ 567458A
Authority
NZ
New Zealand
Prior art keywords
receptor
cell
nls
protein
cells
Prior art date
Application number
NZ567458A
Other languages
English (en)
Inventor
Brian F Oaedowd
Susan R George
Original Assignee
Brian F Oaedowd
Susan R George
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian F Oaedowd, Susan R George filed Critical Brian F Oaedowd
Publication of NZ567458A publication Critical patent/NZ567458A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00Labels used in chemical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
NZ567458A 2002-04-12 2003-04-11 Method of indentifying transmembrane protein-interacting compounds NZ567458A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37170402P 2002-04-12 2002-04-12
US37941902P 2002-05-13 2002-05-13
US38757002P 2002-06-12 2002-06-12
US42289102P 2002-11-01 2002-11-01
US44255603P 2003-01-27 2003-01-27
NZ536063A NZ536063A (en) 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds

Publications (1)

Publication Number Publication Date
NZ567458A true NZ567458A (en) 2009-10-30

Family

ID=29255685

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ567458A NZ567458A (en) 2002-04-12 2003-04-11 Method of indentifying transmembrane protein-interacting compounds
NZ536063A NZ536063A (en) 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ536063A NZ536063A (en) 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds

Country Status (16)

Country Link
US (8) US7309576B2 (enExample)
EP (3) EP1495330B1 (enExample)
JP (4) JP4542342B2 (enExample)
CN (1) CN100399028C (enExample)
AT (1) ATE421697T1 (enExample)
AU (2) AU2003218586B2 (enExample)
CA (1) CA2521946C (enExample)
CY (1) CY1108997T1 (enExample)
DE (1) DE60325953D1 (enExample)
DK (1) DK1495330T3 (enExample)
ES (2) ES2566487T3 (enExample)
MX (1) MXPA04011134A (enExample)
NZ (2) NZ567458A (enExample)
PT (1) PT1495330E (enExample)
SI (1) SI1495330T1 (enExample)
WO (1) WO2003087836A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1495330T3 (da) 2002-04-12 2009-05-18 Brian F O'dowd Fremgangsmåde til at identificere forbindelser, som påvirker transmembran-proteiner
EP2255832A3 (en) * 2004-06-16 2011-02-09 Affinergy, Inc. IFBM's to promote attachment of target analytes
CN1944647B (zh) * 2006-08-23 2010-05-12 华东师范大学 多巴胺受体新亚型d5b基因及编码的蛋白与应用
JP4929462B2 (ja) 2007-01-29 2012-05-09 国立大学法人高知大学 細胞膜上分子と相互作用する化合物の検出方法
JP5213075B2 (ja) * 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および/または処置のための微生物
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
CN102580091B (zh) * 2011-01-12 2014-12-10 中国科学院上海生命科学研究院 增强阿片镇痛剂的镇痛作用的方法及试剂
US8643360B1 (en) * 2012-09-02 2014-02-04 George S. Cargill, III In-water voltage gradient detector
TWI472617B (zh) * 2012-09-17 2015-02-11 Nat Univ Chung Hsing 調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
CN107406838A (zh) 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
BR112017024534A2 (pt) 2015-05-15 2018-07-24 Pioneer Hi Bred Int sistemas de rna-guia/endonuclease cas9 inovadores
AU2016338785B2 (en) 2015-10-12 2022-07-14 E. I. Du Pont De Nemours And Company Protected DNA templates for gene modification and increased homologous recombination in cells and methods of use
US20180273960A1 (en) 2015-10-20 2018-09-27 Pioneer Hi-Bred International, Inc. Methods and compositions for marker-free genome modification
WO2017079026A1 (en) 2015-11-06 2017-05-11 E. I. Du Pont De Nemours And Company Generation of complex trait loci in soybean and methods of use
DK3387134T3 (da) 2015-12-11 2020-12-21 Danisco Us Inc Fremgangsmåder og sammensætninger til øget nukleasemedieret genommodifikation og reducerede virkninger uden for målstedet
EP3390631B1 (en) 2015-12-18 2020-04-08 Danisco US Inc. Methods and compositions for t-rna based guide rna expression
BR112018015348A2 (pt) 2016-01-26 2018-12-18 Pioneer Hi Bred Int método para obter uma planta de milho ceroso, planta, semente, polinucleotídeo-guia e método para produzir uma planta híbrida de milho ceroso
WO2017155717A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017155715A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017155714A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
BR112018076027A2 (pt) 2016-06-14 2019-03-26 Pioneer Hi-Bred International, Inc. método para modificar uma sequência-alvo no genoma de uma célula vegetal; método para editar uma sequência de nucleotídeos no genoma de uma célula vegetal; método para modificar simultaneamente múltiplas sequências-alvo no genoma de uma célula vegetal; método para modificar uma sequênciaalvo de dna no genoma de uma célula vegetal e modelo de modificação de polinucleotídeo
US20190100745A1 (en) 2016-06-20 2019-04-04 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
EA201990924A1 (ru) 2016-10-13 2019-09-30 Пайонир Хай-Бред Интернэшнл, Инк. Создание маиса, устойчивого к северной пятнистости листьев
AU2017375631B2 (en) * 2016-12-12 2023-06-15 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
EP3562796B1 (en) 2016-12-30 2023-04-19 Xcella Biosciences, Inc. Multi-stage sample recovery system
US11519009B2 (en) 2017-01-09 2022-12-06 University Of Massachusetts Complexes for gene deletion and editing
WO2019118463A1 (en) 2017-12-15 2019-06-20 Danisco Us Inc Cas9 variants and methods of use
CN108178790B (zh) * 2018-01-18 2021-09-07 上海药明康德新药开发有限公司 一种将细胞膜分离以便对跨膜蛋白进行dna编码化合物库筛选的方法
CN112020554B (zh) 2018-02-23 2024-10-22 先锋国际良种公司 新颖cas9直系同源物
CA3109984A1 (en) 2018-10-16 2020-04-23 Pioneer Hi-Bred International, Inc. Genome edited fine mapping and causal gene identification
CA3117813A1 (en) 2018-12-06 2020-06-11 xCella Biosciences, Inc. Lateral loading of microcapillary arrays
CA3117228A1 (en) 2018-12-14 2020-06-18 Pioneer Hi-Bred International, Inc. Novel crispr-cas systems for genome editing
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
WO2020206197A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc Methods for polynucleotide integration into the genome of bacillus using dual circular recombinant dna constructs and compositions thereof
CA3136114A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc. Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof
KR102329302B1 (ko) * 2019-09-30 2021-11-22 한국과학기술연구원 도파민 d1형 수용체의 활성 측정용 적색 형광 단백질 기반 바이오센서
US20250064032A1 (en) 2021-12-10 2025-02-27 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
KR102833970B1 (ko) * 2022-02-23 2025-07-17 충남대학교산학협력단 핵수송 신호 펩타이드가 접합된 핵산 전달용 2세대 폴리아미도아민 덴드리머 고분자 유도체
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
EP4627078A1 (en) 2022-12-01 2025-10-08 Danisco US Inc. Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system
WO2024118876A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system
WO2024118882A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a selection marker swapping system
CN121152874A (zh) 2023-03-20 2025-12-16 先锋国际良种公司 具有改变的PAM识别的Cas多肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
WO1999005177A1 (en) 1997-07-28 1999-02-04 The Regents Of The University Of California Methods and compositions for identifying modulators of g-protein-coupled receptors
AU2001241463A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (CCR5) HDGNR10
AU2001284974A1 (en) 2000-08-16 2002-02-25 The Trustees Of Columbia University In The City Of New York Quantitative assessment of erbb/her receptors in biological fluids
DK1495330T3 (da) 2002-04-12 2009-05-18 Brian F O'dowd Fremgangsmåde til at identificere forbindelser, som påvirker transmembran-proteiner

Also Published As

Publication number Publication date
EP1495330A1 (en) 2005-01-12
US20150377896A1 (en) 2015-12-31
JP2013137311A (ja) 2013-07-11
JP6168669B2 (ja) 2017-07-26
ES2566487T3 (es) 2016-04-13
US7794955B2 (en) 2010-09-14
AU2003218586A1 (en) 2003-10-27
JP5870016B2 (ja) 2016-02-24
US20190317105A1 (en) 2019-10-17
HK1073358A1 (en) 2005-09-30
EP2339347A1 (en) 2011-06-29
WO2003087836A1 (en) 2003-10-23
SI1495330T1 (sl) 2009-06-30
US20050287602A1 (en) 2005-12-29
US20180267051A1 (en) 2018-09-20
US9005905B2 (en) 2015-04-14
US20100279318A1 (en) 2010-11-04
CA2521946A1 (en) 2003-10-23
HK1128957A1 (en) 2009-11-13
JP2010112955A (ja) 2010-05-20
JP4542342B2 (ja) 2010-09-15
ATE421697T1 (de) 2009-02-15
US20130084581A1 (en) 2013-04-04
ES2321704T3 (es) 2009-06-10
DK1495330T3 (da) 2009-05-18
AU2009201195B2 (en) 2012-05-03
US7309576B2 (en) 2007-12-18
US20090081691A1 (en) 2009-03-26
EP2073013A1 (en) 2009-06-24
CA2521946C (en) 2013-10-15
JP5187910B2 (ja) 2013-04-24
JP2016026299A (ja) 2016-02-12
PT1495330E (pt) 2009-04-23
DE60325953D1 (de) 2009-03-12
JP2005522227A (ja) 2005-07-28
CN1646917A (zh) 2005-07-27
AU2003218586B2 (en) 2009-01-08
EP2073013B1 (en) 2016-01-06
AU2009201195A1 (en) 2009-04-23
CN100399028C (zh) 2008-07-02
US8298777B2 (en) 2012-10-30
US20170336418A1 (en) 2017-11-23
EP1495330B1 (en) 2009-01-21
MXPA04011134A (es) 2005-08-15
NZ536063A (en) 2008-08-29
CY1108997T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
AU2009201195B2 (en) Method of Identifying Transmembrane Protein-Interacting Compounds
EP1477806A1 (en) Method of determining ligand
AU2015203835B2 (en) Method of Identifying Transmembrane Protein-Interacting Compounds
CA2824698C (en) Method of identifying transmembrane protein-interacting compounds
AU2012207061B2 (en) Method of Identifying Transmembrane Protein-Interacting Compounds
HK1128957B (en) Method of identifying transmembrane protein-interacting compounds
HK1073358B (en) Method of identifying transmembrane protein-interacting compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: OMEROS CORPORATION, US

Free format text: OLD OWNER(S): BRIAN F. O'DOWD; SUSAN R. GEORGE

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 APR 2016 BY AJ PARK

Effective date: 20130307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2019 BY COMPUTER PACKAGES INC.

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

EXPY Patent expired